Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single Center study-Reference-Cited by-同舟云学术

Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single Center study

Published:2021-04-30 Issue: Volume: Page:1-9
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Ricceri Federica¹,Rosi Elia¹,Di Cesare Antonella¹,Scandagli Ilaria¹,Fastame Maria Thais¹,Prignano Francesca¹

Affiliation:

1. Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2021.1922573

Reference11 articles.

1. Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderateto-severe plaque psoriasis. Br J Dermatol. 2018;178:509–519.

2. Carrascosa J, Jacobs I, Petersel D, Strohal R. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther. 2018;8(2):173–94.

3. Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177(6):1495–502.

4. Generics and Biosimilars Initiative (GaBI). Biosimilars approved in Europe. http://www.gabio nline.net/Biosimilars/General/Biosimilar s-appro ved-in-Europ e. Accessed 18 Dec 2019

5. Egeberg A. Real world SB4 (etanercept biosimilar) use in patients with psoriasis: data from British Association of Dermatologist Biologic Interventions Registry (BADBIR): Abstract #P1839. 27th EADV Congress; Paris, France; 2018.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Documento de consenso sobre los medicamentos biosimilares en enfermedades inmunomediadas en España;Reumatología Clínica;2023-10

2. Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain;Reumatología Clínica (English Edition);2023-10

3. The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance;EMJ Gastroenterology;2022-11-04